Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pain Management

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1534058

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1534058

Pain Management Drugs

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Pain Management Drugs Market to Reach US$92.9 Billion by 2030

The global market for Pain Management Drugs estimated at US$76.3 Billion in the year 2023, is expected to reach US$92.9 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Opioid Drugs, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$24.9 Billion by the end of the analysis period. Growth in the NSAIDS segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.8 Billion While China is Forecast to Grow at 5.5% CAGR

The Pain Management Drugs market in the U.S. is estimated at US$20.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$18.6 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Pain Management Drugs Market - Key Trends and Drivers Summarized

Pain management drugs encompass a broad spectrum of medications designed to alleviate various types of pain, ranging from acute and chronic pain to pain resulting from surgeries or medical conditions such as arthritis, cancer, and neuropathy. These drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, anticonvulsants, antidepressants, and topical analgesics. Each category of pain management drugs operates through distinct mechanisms to target different pain pathways, providing tailored relief to patients. The market for these drugs is vast and continually evolving, driven by ongoing research and development efforts aimed at enhancing efficacy, reducing side effects, and addressing the opioid crisis through the development of non-addictive painkillers.

Innovations in pain management are being fueled by advancements in biotechnology and pharmacology. The emergence of biologics and biosimilars, for instance, represents a significant leap forward, offering targeted pain relief with potentially fewer side effects. Additionally, the development of extended-release formulations and transdermal delivery systems has improved the convenience and adherence to pain management regimens. Personalized medicine is also making headway in this field, with genetic testing and biomarker identification enabling more precise and effective treatment plans tailored to individual patient needs. These technological strides are complemented by a growing body of clinical evidence supporting the use of multimodal pain management strategies, which combine different classes of drugs and non-pharmacological interventions to optimize pain relief and enhance patient outcomes.

The growth in the pain management drugs market is driven by several factors. A significant driver is the rising prevalence of chronic pain conditions such as arthritis, back pain, and neuropathic pain, which increases the demand for effective pain management solutions. Advances in drug delivery technologies, including transdermal patches and implantable devices, have expanded the addressable market by offering new ways to administer pain relief. The aging global population also contributes to market growth, as older adults are more likely to suffer from chronic pain conditions. Additionally, increasing awareness and diagnosis of pain-related conditions have propelled market demand. Regulatory support for the development of new pain management drugs, along with initiatives to combat the opioid crisis by promoting safer alternatives, further stimulates market expansion. Moreover, the growing trend of personalized medicine, which tailors pain management therapies to individual genetic profiles, drives adoption and enhances treatment efficacy. Collectively, these factors are shaping a dynamic and rapidly expanding market for pain management drugs.

Select Competitors (Total 86 Featured) -

  • AdvaCare Pharma
  • Daiichi Sankyo Co., Ld.
  • Eisai Co., Ltd.
  • Eli Lilly & Company
  • Endo Pharmaceuticals, Inc.
  • Fresenius Kabi USA
  • IBSA Institute Biochimique SA
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Neuracle Lifesciences Private Limited
  • Novartis AG
  • Pfizer, Inc.
  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.;
Show more
Product Code: MCP26845

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Pain Management Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Pain Conditions Spurs Demand for Effective Therapies
    • Aging Population Expands Addressable Market Opportunity for Pain Management Drugs
    • Advances in Drug Delivery Technologies Propel Growth in Market Adoption
    • Development of Non-Addictive Painkillers Strengthens Business Case for Safer Alternatives
    • Personalized Medicine and Genetic Testing Drive Adoption of Tailored Pain Therapies
    • Emergence of Biologics and Biosimilars Generates New Market Opportunities
    • Increasing Awareness and Diagnosis of Pain-Related Conditions Accelerates Demand
    • Integration of Multimodal Pain Management Strategies Sustains Growth in Treatment Approaches
    • Here's How Extended-Release Formulations Enhance Patient Adherence
    • Technological Innovations in Transdermal and Implantable Devices Throw the Spotlight On Advanced Pain Relief Methods
    • Expansion of Healthcare Infrastructure in Emerging Markets Generates Demand for Pain Management Drugs
    • Rising Trend of Non-Pharmacological Interventions in Pain Management Generates Complementary Market Opportunities
    • Increasing Investment in Biotechnology Propels Growth in Novel Pain Therapies
    • Adoption of Telemedicine and Digital Health Technologies Expands Access to Pain Management Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pain Management Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pain Management Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Opioid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Opioid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Opioid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for NSAIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Non-Narcotic Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Non-Narcotic Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Non-Narcotic Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antimigraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antimigraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antimigraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Chronic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Chronic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Chronic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Acute Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Acute Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Acute Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • JAPAN
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • CHINA
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • EUROPE
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pain Management Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • FRANCE
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • GERMANY
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pain Management Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • INDIA
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pain Management Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pain Management Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
  • AFRICA
    • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!